Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al.

被引：0

作者：

Eric L Matteson

Tim Bongartz

Alex J Sutton

Iain Buchan

机构：

[1] Mayo Clinic College of Medicine,Division of Rheumatology

[2] University of Leicester,Department of Health Sciences

[3] University of Manchester,Northwest Institute for Bio

来源：

Arthritis Research & Therapy | / 8卷

关键词：

Placebo; Rheumatoid Arthritis; Infliximab; Etanercept; Detection Threshold;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 11 条

[1]

Dixon W(2006)Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz Arthritis Res Ther 8 111-2286

[2]

Silman A(2006). JAMA 295 2275-1545

[3]

Bongartz T(2004)Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systemic review and meta-analysis of rare harmful effects in randomized controlled trials J Rheumatol 31 1538-117

[4]

Sutton AJ(2006)Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis N Engl J Med 355 113-undefined

[5]

Sweeting MJ(undefined)Time-to-event analyses for long-term treatments: The APPROVe trial undefined undefined undefined-undefined

[6]

Buchan I(undefined)undefined undefined undefined undefined-undefined

[7]

Matteson EL(undefined)undefined undefined undefined undefined-undefined

[8]

Montori V(undefined)undefined undefined undefined undefined-undefined

[9]

Stern R(undefined)undefined undefined undefined undefined-undefined

[10]

Wolfe F(undefined)undefined undefined undefined undefined-undefined

← 1 2 →